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Abstract
Background and aims: Hepatitis E virus (HEV), as an emerging zoonotic pathogen, 
is a leading cause of acute viral hepatitis worldwide, with a high risk of developing 
chronic infection in immunocompromised patients. However, the global epidemiol-
ogy of HEV infection has not been comprehensively assessed. This study aims to map 
the global prevalence and identify the risk factors of HEV infection by performing a 
systematic review and meta-analysis.
Methods: A systematic searching of articles published in Medline, Embase, Web 
of science, Cochrane and Google scholar databases till July 2019 was conducted 
to identify studies with HEV prevalence data. Pooled prevalence among different 
countries and continents was estimated. HEV IgG seroprevalence of subgroups was 
compared and risk factors for HEV infection were evaluated using odd ratios (OR).
Results: We identified 419 related studies which comprised of 1 519 872 individu-
als. A total of 1 099 717 participants pooled from 287 studies of general popula-
tion estimated a global anti-HEV IgG seroprevalence of 12.47% (95% CI 10.42-14.67; 
I2 = 100%). Notably, the use of ELISA kits from different manufacturers has a sub-
stantial impact on the global estimation of anti-HEV IgG seroprevalence. The pooled 
estimate of anti-HEV IgM seroprevalence based on 98 studies is 1.47% (95% CI 1.14-
1.85; I2 = 99%). The overall estimate of HEV viral RNA-positive rate in general popu-
lation is 0.20% (95% CI 0.15-0.25; I2 = 98%). Consumption of raw meat (P = .0001), 
exposure to soil (P < .0001), blood transfusion (P = .0138), travelling to endemic areas 
(P = .0244), contacting with dogs (P = .0416), living in rural areas (P = .0349) and 
receiving education less than elementary school (P < .0001) were identified as risk 
factors for anti-HEV IgG positivity.
Conclusions: Globally, approximately 939 million corresponding to 1 in 8 individu-
als have ever experienced HEV infection. 15-110 million individuals have recent or 
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1  | INTRODUC TION
Hepatitis E virus (HEV) as a positive-sense single-stranded RNA 
virus is a leading cause of acute viral hepatitis worldwide. The infec-
tion is usually asymptomatic or self-limiting in the general popula-
tion. However, acute infection in pregnant women may cause severe 
clinical outcomes, including fulminant hepatic failure with high mor-
tality rate reaching up to 20%-30%.1 These patients are mostly from 
resource-limited regions. In European countries, HEV infection has 
been frequently reported to bear high risk of developing into chronic 
hepatitis in immunocompromised individuals, in particular organ 
transplant patients.2,3 Thus, HEV is truly imposing a global health 
burden in both developing and developed countries.
Currently, eight distinct genotypes (GTs) of HEV have been clas-
sified.4 GT 1-4 are known to be the main threat to humans. GT 1 and 
GT 2 are restricted to human and mainly transmit through contami-
nated water causing acute hepatitis. GT 3 and GT 4 are zoonotic and 
have been identified in a wide spectrum of hosts, including human, 
swine, wild boar, goat, cattle, deer, camel and yak.5 Both GT 3 and 
GT 4 can cause chronic infection in organ transplant patients,2,6 
and consumption of raw or undercooked animal meat has been rec-
ognized as the main routes of causing sporadic cases in developed 
countries.7 In fact, the host range of HEV is ever expanding and the 
implications of the rare GTs and the newly discovered strains in 
human health remain largely uncertain.7 This further complicates the 
transmission and the risk of HEV infection. In addition to the classi-
cal waterborne and foodborne transmission routes, blood transfu-
sion-mediated transmission has been reported in organ transplant 
patients.8 Person-to-person transmission has also been proposed.9 
Intriguingly, recent evidence has indicated that pet animals including 
dogs, cats, rabbits and horses might be accidental hosts for HEV and 
constitute a potential source for transmitting to human.10,11 Thus, 
there is an urgent need to comprehensively understand the risks for 
HEV infection, in order to device preventive measures.
Globally, it has been roughly estimated that one-third of the pop-
ulation are living in HEV endemic areas.12 More recently, substantial 
efforts have been dedicated to systematically evaluate HEV preva-
lence in different continents (eg the Americas and Europe),13,14 dif-
ferent countries (eg industrialized countries, China, Iran, Brazil and 
Somalia)15–17 and special populations or settings (eg blood donors, 
swine workers and outbreak setting).18–20 Most of these studies are 
based on seropositivity of anti-HEV IgG antibody. Anti-HEV IgG 
antibody developed post-infection usually persists for many years, 
and is thus regarded as a marker for past infection.21,22 In contrast, 
anti-HEV IgM antibody is short-lived up to a few months, thus 
considered as evidence of recent or current infection. Detection of 
HEV RNA is a bona fide marker for active ongoing infection. In this 
study, we aimed to systematically estimate the global burden of HEV 
infection. More specifically, we have mapped the global prevalence 
of past, recent and ongoing HEV infection and evaluated the key risk 
factors of infection.
2  | MATERIAL S AND METHODS
2.1 | Data sources and searches
A systematic search was conducted in Medline, Embase, Web of 
science, Cochrane CENTRAL and Google scholar. Databases were 
searched for articles in the English language from inception until July 
2019. All searches from database were performed by a biomedical in-
formation specialist of the medical library, with an exhaustive set of 
search terms related to hepatitis E virus infection and epidemiology 
(the full search strategies are provided in the Supporting Information 
S1). This study is reported in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis.23 No institutional 
review board approval was required for this meta-analysis because 
our study only included data which had been published previously.
2.2 | Study selection
Studies were included if they met the following criteria: (a) Studies 
which contained data about seroprevalence of anti-HEV IgG, anti-
HEV IgM or HEV RNA positivity, (b) Studies contained mixed popu-
lation were excluded unless they clearly and explicitly reported the 
ongoing HEV infection. Our study highlights the substantial burden of HEV infection 
and calls for increasing routine screening and preventive measures.
K E Y W O R D S
epidemiology, hepatitis E virus, prevalence, risk factors, seroprevalence
Key points
• This meta-analysis reports the latest estimation that ap-
proximately 939 million of the global population have 
ever experienced hepatitis E virus (HEV) infection, 
and 15-110 million individuals have recent or ongoing 
infection.
• These findings indicate that HEV infection has emerged 
as a global health burden requiring implementation of 
specific control measures.
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prevalence for each group, (c) Studies contained information of risk 
factors related to HEV infection and (d) Studies which focused on 
the HEV prevalence in human beings.
Studies were excluded if they met the following criteria: (a) 
Studies are systematic review, meta-analysis, case reports, perspec-
tives and abstracts, (b) None human studies, (c) No primary data or 
incomplete data, (d) Duplicate data, (e) Studies with <50 individuals 
were excluded in order to decrease bias caused by small population 
and (f) Studies concerning about HEV outbreaks, since the preva-
lence and outcome of HEV infection in these studies would dramat-
ically differ from those of the general population.
Two reviewers (PL and JL) worked independently to determine 
whether a study met inclusion criteria, abstracted information to 
assess the methodological validity of each candidate study and ex-
tracted data with structured data collection forms. The reviewers 
resolved discrepancies by jointly reviewing the study in question. If 
no consensus was reached, a third reviewer (QP), unaware of prior 
determinations, functioned as an arbiter.
2.3 | Data extraction and quality assessment
Eligible studies were further divided into three study populations: 
general population, occupational population and special popula-
tion. General population included people without apparent risk 
factors and could be comprised of blood donors, pregnant women, 
healthy individuals and hospital attendants. For general population, 
individuals were further divided into subgroups by gender, differ-
ent age ranges, study period (1993-2006 or 2007-2019), country 
development classification (developing and developed countries), 
gross national income classification of each country (high, upper 
middle, lower middle and low income) and ELISA kit manufactur-
ers. More importantly, OR analysis of anti-HEV IgG seropositivity 
was conducted in possible risk factors including living area (urban or 
rural), consumption of raw meat, exposure to soil, contacting with 
cat or dog, education level (elementary school or above elementary 
school), intravascular drug use (IDU), water source (tap, well or river), 
man having sex with man (MSM), transfusion history and travel-
ling history to endemic areas. Occupational population represents 
people who had been in frequent contact with pigs or pig products, 
including veterinarians, swine workers, slaughterhouse workers 
and pork sellers. Special populations are further categorized into 
four groups as followings: patients with acute hepatitis (caused by 
hepatitis B virus, hepatitis C virus or other unknown hepatitis), indi-
viduals with human immunodeficiency virus (HIV) infection, people 
who underwent haemodialysis and organ transplant recipients. Two 
independent reviewers (PL and JY) extracted data, with discrepan-
cies and disagreements resolved by discussion. We extracted data 
on first author, country, continent, publication date, anti-HEV IgG 
prevalence, anti-HEV IgM prevalence, HEV RNA positivity, subgroup 
information of anti-HEV IgG prevalence and HEV-related risk fac-
tors using data extracting forms. When multiple publications were 
identified that reported on the same populations and outcomes, only 
the most representative and comprehensive study was included for 
further meta-analysis in order to avoid duplicate data. The quality of 
studies was assessed using the Joanna Briggs Institute checklist for 
prevalence studies, which enabled assessment of included studies in 
relation to risk of bias, rigour and transparency.24 Studies scoring 1-3 
were defined as low quality, 4-6 as average quality and 7-9 as high 
quality (Table S1). Studies were not excluded on the basis of their 
quality score to increase transparency and to ensure all available evi-
dence in this area was reported.
2.4 | Statistics analysis
After checking for consistency, the Metaprop module in the R-3.5.3 
statistical software package was used for meta-analysis. A 95% con-
fidence interval (95% CI) was estimated using Wilson score method, 
and pooled seroprevalence was calculated with the DerSimonian-
Laird random effects model with Freeman-Tukey double arcsine 
transformation. Heterogeneity across the included studies was as-
sessed using the Cochran Q statistics and I2 statistics, with I2 statis-
tics 25%-50%, 50%-75% and >75% considered as mild, moderate and 
severe heterogeneity respectively. When heterogeneity was higher 
than 50%, a random effect model will be used. ORs were used to 
report the risk factors for HEV infection. ORs and their 95% CI were 
extracted directly from studies when available, with adjusted ORs 
extracted preferentially over unadjusted ORs. If included studies 
did not report ORs, crude ORs were calculated from extracted data. 
We then pooled the ORs using the DerSimonian and Laird random 
effect models, with the heterogeneity estimated from the Mantel-
Haenszel model. Funnel plots and Egger regression test were used 
to assess potential publication biases. Additionally, we performed 
sensitivity analyses using “metainf” in a random model to investigate 
the effects of population source and potentially unrepresentative 
samples. The estimated prevalence of anti-HEV IgG, IgM and HEV 
RNA infection was based on the global population of 7 530 000 000 
on 20 July 2019 (https://popul ation.io).
3  | RESULTS
3.1 | Global prevalence of HEV infection
Our search retuned 8153 records, of which 419 met the inclusion 
criteria (Figure 1). In total, participants from 302 studies related 
to general population, and 287 studies were pooled to estimate a 
global anti-HEV IgG seroprevalence of 12.47% (1 099 717 individu-
als included; 95% CI 10.42-14.67; I2 = 100%; Figure 2A; Figure S1). 
The pooled estimate of anti-HEV IgM seroprevalence based on 98 
studies is 1.47% (479 001 individuals; 95% CI 1.14-1.85; I2 = 99%; 
Figure 2B; Figure S2). The overall estimate of HEV RNA-positive rate 
in the general population is 0.20% (3 444 752; 95% CI 0.15-0.25; 
I2 = 98%; Figure 2C; Figure S3). We also stratified data to estimate 
the HEV prevalence in 75 countries among six continents (excluding 
4  |     LI et aL.
Antarctica). The highest anti-HEV IgG seropositivity rate was found 
in Africa (22 377; 21.76%, 95% CI 13.05-31.98; I2 = 100%), followed 
by Asia (681 373; 15.80%, 95% CI 13.29-18.49; I2 = 100%), Europe 
(132 419; 9.31%, 95% CI 7.35-11.48; I2 = 99%), North America 
(71 989; 8.05%, 95% CI 5.47-11.09; I2 = 99%), South America (14 586; 
7.28%, 95% CI 4.83-10.19; I2 = 97%) and Oceania (1563; 5.99%, 95% 
CI 1.22-14.03; I2 = 96%; Figure S4). Besides, the anti-HEV IgM se-
roprevalence was 3.09% (5001; 95% CI 1.49-5.24; I2 = 93%), 1.86% 
(141 565; 95% CI 1.34-2.46; I2 = 98%), 0.79% (146 322; 95% CI 0.30-
1.51; I2 = 99%), 0.22% (12 197; 95% CI 0.00-0.74; I2 = 91%) and 2.43% 
(2680; 95% CI 0.43-6.00; I2 = 96%) for Africa, Asia, Europe, North 
America and South America respectively (Figure S5). In addition, the 
HEV RNA positivity rate was 0.00% (278; 95% CI 0.00-0.35), 0.93% 
(727 744; 95% CI 0.48-1.52; I2 = 99%), 0.08% (2 441 774; 95% CI 
0.05-0.11; I2 = 95%), 0.00% (34 761; 95% CI 0.00-0.02; I2 = 45%), 
0.00% (74 131; 95% CI 0.00-0.01) and 0.18% (1054; 95% CI 0.00-
1.36; I2 = 81%) for Africa, Asia, Europe, North America, Oceania and 
South America respectively (Figure S6). HEV prevalence varies sub-
stantially among countries, from 0.25% (Tanzania, 95% CI 0.00-0.97) 
to 74.76% (South Sudan, 95% CI 68.61-80.44) of anti-HEV IgG, from 
0.00% (Mongolia, 95% CI 0.00-0.08; Bulgaria, 95% CI 0.00-0.13) to 
19.83% (United Arab, 95% CI 16.35-23.56) of anti-HEV IgM and from 
0.00% (Benin, Malawi, Australia, Canada, Brazil) to 6.75% (France, 
95% CI 0.14-22.04) of HEV RNA positivity (Table 1; Figures S1-S3). 
We also collected data of HEV GTs, with the finding that HEV GT 
1 infection occasionally occurred in China and frequently in India, 
and GT 3 was widely distributed in European countries. GT 3 was 
also prevalent in Japan and Korea, whereas GT 4 infection mainly 
emerged in China (Figure 3; Table S2). Based on our comprehensive 
estimates, approximately 938 991 000 individuals corresponding to 
1/8 of the global population have ever experienced HEV infection 
based on anti-HEV IgG positivity. Importantly, we estimated approx-
imately 110 691 000 global individuals with current or recent HEV 
infection and 15 060 000 individuals with ongoing HEV infection 
based on anti-HEV IgM or viral RNA positivity respectively.
We next performed subgroup analysis of anti-HEV IgG positivity 
rate in general population. General population of six different con-
tinents were further divided into seven age groups, including age 
range of 0-9, 10-19, 20-29, 30-39, 40-49, 50-59 and above 60-year-
old. The corresponding pooled anti-HEV IgG-positive rates are 7.73% 
(6977 individuals included; 95% CI 2.29-16.02; I2 = 99%), 9.03% 
(14 452 individuals; 95% CI 3.78-16.25; I2 = 99%), 10.78% (33 365; 
95% CI 7.44-14.64; I2 = 99%), 14.17% (23 217; 95% CI 10.27-18.57; 
I2 = 99%), 21.53% (21 324; 95% CI 16.82-26.65; I2 = 99%), 24.48% 
(17 474; 95% CI 18.56-30.93; I2 = 99%) and 27.47% (23 924; 95% CI 
21.07-34.36; I2 = 99%) respectively (Figure 4; Figures S7 and S8). 
The positive rate is slightly higher in male (129 569; 13.39%, 95% 
CI 11.34-15.59; I2 = 99%) compared to female (120 264; 12.25%, 
F I G U R E  1   Study selection
Records identified through database 
searching
(n = 8095)
Additional records identified 
through other sources
(n = 58)
Records after duplicates removed
(n = 4271)
Records screened
(n = 4271) 
Records excluded
(n = 3296)
2969 studies were not related with HEV 
and HEV prevalence items.
106 studies were reviews, abstract, 
systematic review.
206 studies without enough information.
15 studies were not in English.
Full-text articles assessed 
for eligibility
(n = 975) 
Full-text articles excluded, 
with reasons (n = 556)
79 studies excluded for case report or 
clinical treatment research.
81 studies were duplicate publications.
263 studies were excluded for improper 
study design.
45 studies with small samples..
88 studies were excluded incomplete 
information.Studies included in 
qualitative synthesis
(n = 419)
Studies included in 
quantitative synthesis 
(meta-analysis)
(n = 419)
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95% CI 10.05-14.63; I2 = 99%; Figure 4; Figure S9). To clarify the 
HEV prevalence among regions with different levels of economic 
development, we firstly calculated the anti-HEV IgG prevalence 
in high-income countries, upper middle income countries, lower 
middle income countries and low income countries. We estimated 
the anti-HEV IgG positivity of 8.84% (424 905; 95% CI 6.79-11.14; 
I2 = 100%) in high-income countries, 12.79% (618 638; 95% CI 10.81-
14.92; I2 = 100%) in upper middle income countries, 19.04% (40 593; 
95% CI 13.25%-25.60%; I2 = 100%) in lower middle income countries 
and 30.44% (5781; 95% CI 16.60-46.39; I2 = 99%) in low income 
countries (Figure 4; Figure S10). The pooled estimate of anti-HEV 
IgG seroprevalence was 14.83% (689 452; 95% CI 12.98-16.77; 
I2 = 100%) in developing countries compared to 8.59% (401 513; 95% 
CI 6.46-10.99; I2 = 100%) in developed countries (Figure 4; Figure 
S11). Of the global HEV prevalence during the period of 1993-2019, 
we estimated anti-HEV IgG-positive rate of 9.43% (79 998; 95% CI 
F I G U R E  2   (A) The global 
seroprevalence of anti-HEV IgG antibody 
(B) The global seroprevalence of anti-HEV 
IgM antibody (C) The global prevelence of 
HEV RNA prositivity
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6.11-13.37; I2 = 100%) during 1993-2006 and 13.65% (1 019 719; 
95% CI 11.15-16.35; I2 = 100%) during 2007-2019 (Figure 4, Figure 
S12).
3.2 | Prevalence of HEV infection in occupational 
population and special population
Anti-HEV IgG seroprevalence data from veterinarians, swine work-
ers, slaughters and pork sellers were collected to estimate the over-
all anti-HEV seroprevalence in occupational population. Based on 43 
studies with 8776 occupational individuals, the overall seropositiv-
ity of anti-HEV IgG is 24.04% (95% CI 18.55-29.99; I2 = 97%; Figure 
S13). In total, data from 126 studies were extracted to analyse the 
prevalence in special populations. The overall anti-HEV IgG, anti-
HEV IgM and viral RNA-positive rates are 15.43% (95% CI 12.82-
18.24; I2 = 98%), 3.21% (95% CI 1.77-5.06; I2 = 98%) and 1.10% (95% 
CI 0.53-1.87; I2 = 97%) respectively (Figures S14-S16). Among these 
special populations, patients with acute hepatitis have the highest 
positive rate of anti-HEV IgG (21.49%, 95% CI 12.65-31.92; I2 = 99%), 
anti-HEV IgM (8.62%, 95% CI 4.16-14.51; I2 = 99%) and viral RNA 
(5.57%, 95% CI 2.26-10.21; I2 = 99%; Figures S17-S19). The anti-HEV 
IgG-positive rates in two special groups are higher than that in gen-
eral population, with 16.91% (95% CI 12.64-21.67; I2 = 98%) in the 
HIV population and 13.10% (95% CI 9.34-17.39; I2 = 96%) in hae-
modialysis population, while it is slightly lower in organ transplant 
recipients with 11.68% (95% CI 7.91-16.06; I2 = 97%) seropositivity 
(Figures S20-S27; Table S5).
3.3 | Risk factors of HEV
We investigated the potential risk factors for HEV in the general pop-
ulation (Figure S28). Significant rising effects on anti-HEV IgG sero-
positivity were observed in consumption of raw meat (OR 1.45, 95% 
CI 1.20-1.76, P = .0001), exposure to soil (OR 1.52, 95% CI 1.24-1.86, 
P < .0001), blood transfusion (OR 1.61, 95% CI 1.10-2.36, P = .0138), 
travelling to endemic areas (OR 1.39, 95% CI 1.04-1.84, P = .0244), con-
tacting with dogs (OR 1.45, 95% CI 1.01-2.07, P = .0416), living in rural 
areas (OR 0.80, 95% CI 0.65-0.98, P = .0349) and receiving education 
less than elementary school (OR 1.71, 95% CI 1.41-2.07, P < .0001). 
No statistically significant differences were identified for anti-HEV 
IgG positivity in respect to different water source (P = .0909), IDU 
experience (P = .4321), MSM experience (P = .5576) and contacting 
with cats (P = .4791; Figure S29-S39). Sensitivity analysis detected no 
study having an obvious effect influence to the pooled estimates of 
HEV prevalence in the general population (Table S3).
3.4 | Anti-HEV IgG detection rate of different 
ELISA kits
We finally analysed the detection rates of the ELISA kits from six 
manufacturers. The detection rates of anti-HEV IgG seropositiv-
ity vary dramatically, with the highest of Wantai assay (20.72%, 
95% CI 2.07-9.84; I2 = 100%) followed by MP Diagnostics (10.75%, 
95% CI 4.55-19.15; I2 = 100%), Dia.Pro (8.89%, 95% CI 6.68-
11.38; I2 = 97%), Mikrogen (8.60%, 95% CI 4.65-13.62; I2 = 98%), 
F I G U R E  3   Hepatitis E virus genotype distribution in our study
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Genelabs Diagnostics (6.22%; 95% CI 3.42-9.77; I2 = 98%) and 
Abbott Laboratories (5.27%, 95% CI 2.07-9.84; I2 = 100%) (Figure 
S40; Table S4).
4  | DISCUSSION
It has been estimated that one-third of the global population, repre-
senting over two billion people, live in HEV endemic areas at risk of 
infection.12 This has been widely misinterpreted as that 2.3 billion 
of the population have been infected with HEV.25 In fact, the true 
burden of hepatitis E remains largely unknown.26 In this study, we 
have systematically and comprehensively assessed the global HEV 
prevalence by retrieving data from 75 countries of the six conti-
nents. We estimated that 12.47% of the global population, corre-
sponding to approximately 939 million individuals, have experienced 
past infection of HEV based on their seropositivity of anti-HEV 
IgG antibody. Africa and Asia have been previously recognized for 
the high prevalence of HEV.27,28 Our estimates confirm the high 
seroprevalence rates of 21. 76% and 15.80% in Africa and Asia re-
spectively. For Europe, we estimated a prevalence rate of 9.31%, 
which is substantially lower than a previous estimation of 16.90% 
from a meta-analysis performed in 2016.14 A possible explanation 
for the disparity could be that they collected fewer studies and in-
cluded small size populations, and thus is prone to cause more bias. 
In Americas, we observed a slightly higher seroprevalence rate in 
North (8.05%) compared to South (7.28%) America, which is consist-
ent with the results from a recent meta-analysis.13
Of a technical note, it has been well-realized that there are sub-
stantial differences in sensitivity and specificity of the anti-HEV IgG 
ELISA kits from different manufacturers.29,30 Our results largely 
agree with the literature that the Wantai assay has the highest sen-
sitivity and has been most widely used.31 Thus, the use of different 
anti-HEV IgG ELISA kits may partially explain the disparities in esti-
mates among different studies, and caution should be taken when 
interpreting the seroprevalence rate in this respect.
The bona fide disease burden of HEV lies in the actively infected 
patients. The global burden caused by GT 1 and GT 2 HEV in Africa 
and Asia has been mathematically modelled for 2005. Among the 4.7 
billion people in these regions corresponding to 72.8% of the global 
population in 2005, it has been estimated as 20 million incident HEV 
infections, 3.4 million symptomatic cases, 70 000 deaths and 3000 
F I G U R E  4   Anti-hepatitis E virus (HEV) IgG seroprevalence among six subgroups
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stillbirths.32 In 2011, WHO reported 14 million symptomatic cases 
annually worldwide with 300 000 deaths and 5200 stillbirths.33 
Hypothetically, if both estimates are accurate, there would be about 
10 million symptomatic cases annually from developed countries, 
which are mainly caused by the zoonotic GT 3 strains. This clearly 
disagrees with the vast majority of the current literature that we do 
not expect the burden in respect to symptomatic infection would be 
three times in developed compared to developing countries. In this 
study, we have estimated approximately 110 million individuals with 
recent/current infection based on anti-HEV IgM antibody positivity 
and 15 million with ongoing infection based on HEV RNA positivity. 
As viral RNA persists for a few weeks and anti-HEV IgM antibody 
for a few months,34 the annually global infections are probably at 
a range of hundred(s) millions. However, the available data regard-
ing anti-HEV IgM antibody or viral RNA positivity are very limited. 
Thus, our estimates may have biases, and we were not able to fur-
ther sub-analyse regional prevalence, GT-specific burden or clinical 
outcome, which require future studies in these aspects.
Accumulating knowledge on HEV biology and transmission 
routes has facilitated the identification of risk factors for the infec-
tion. A wide range of domestic or wild animals have been recognized 
as reservoirs for the zoonotic strains. Consumption of uncooked 
meat or meat product from swine, wild boar or deer has been widely 
reported to cause GT 3 HEV infection in European countries.35,36 As 
expected, consumption of raw meat is an important risk factor re-
vealed by our meta-analysis. This is in line with previous reports that 
humans with occupational exposure to pigs are at a high risk of HEV 
infection.37,38 In this study, we observed twofold higher anti-HEV 
seropositivity in occupational population who had frequent contact 
with pig or pig products compared to the general population.
The host range for HEV is ever expanding and cross-species 
infections commonly occur.7 Intriguingly, recent evidence has in-
dicated that companion animals including dogs, cats, rabbits and 
horses might be accidental hosts for HEV and might constitute a 
source for HEV transmission to human.10,11,39 Transmission of rat 
HEV to human has been recently reported in Hong Kong.40 Dogs 
and cats are the most common household pets. Previous studies 
have reported that seroprevalence of HEV antibodies in dogs ranges 
from 0.8% in the UK,41 6.79% in Brazil,42 17.8% to 36.55% in differ-
ent regions of China,10,11 22.7% in India43 and 56.6% in Germany.44 
Interestingly, when comparing with the general population, veteri-
narians and dog farm staff who are frequently exposed to dogs have 
significantly higher anti-HEV antibody positivity.10 The anti-HEV 
seroprevalence rates in cats have been reported to be 6.28% in 
China,11 8.1% in Korea45 and 33% in Japan.46 In this study, we found 
that people who frequently contact with dogs have higher anti-HEV 
IgG seropositivity. This was not found in people who contact with 
cats, but the number of studies is very limited. These results call 
more attention to address the potential role of pets in HEV zoonotic 
transmission, although currently it remains unconfirmed whether 
pets are reservoirs, requiring further investigation.
Previous studies have indicated the differences of HEV sero-
prevalence between rural and urban areas.47–49 We found that rural 
compared to urban residents have higher risk of HEV infection. This 
largely agrees with our findings that high exposure to soil is also a 
risk factor. In addition, we observed the high risk of HEV infection 
in individuals with lower education levels, consistent with previous 
studies.50,51 Conceivably, this population are more likely living in 
rural areas with compromised sanitation conditions and more fre-
quent exposure to animals or soil. Although we did not find differ-
ences of HEV prevalence with respect to different water source, this 
does not contradict to the fact that contaminated water is the main 
source of GT 1 infection, especially during outbreak. In our study, 
we have excluded studies related to outbreak, and the number of 
included studies reporting water source is also very limited, which 
may cause bias.
Of note, there are some limitations of our study. Firstly, the 
number of available studies, in particular on anti-HEV IgM antibody 
and viral RNA positivity, is limited. We were also not able to further 
analyse detailed regional prevalence, GT-specific burden or clinical 
outcome. Secondly, we have focused on HEV prevalence, but did 
not estimate the incidence, which is also very relevant for assessing 
the disease burden. Thirdly, the assays used for HEV detection are 
heterogeneous in sensitivity and specificity, which may affect the 
estimates. Fourthly, publication bias existed in our study which was 
reflected in Funnel and Egger test (Figures S41-S42).
In summary, we found that 1/8 of the global population, cor-
responding to over 900 million individuals, have ever encountered 
HEV infection. Importantly, 15-110 million individuals are experienc-
ing recent or ongoing infection. Consuming raw meat, exposing to 
soil, blood transfusion, travelling to endemic areas, contacting with 
dogs, living in rural areas and receiving lower level of education were 
identified as risk factors for HEV infection. Thus, our results bear 
important implications for assessing the global burden and devising 
preventive measures for controlling HEV infection.
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